Highly consistency of PIK3CA mutation spectrum between circulating tumor DNA and paired tissue in lung cancer patients

被引:0
作者
Liu, Yan [1 ]
Li, Hui [1 ]
Li, Xiang [1 ]
Zhang, Tingting [2 ]
Zhang, Yang [2 ]
Zhu, Jing [2 ]
Cui, Heran [3 ]
Li, Rixin [3 ]
Cheng, Ying [1 ,2 ]
机构
[1] Jilin Canc Hosp, Jilin Prov Key Lab Mol Diagnost Lung Canc, Translat Oncol Res Lab Jilin Prov, Changchun 130012, Peoples R China
[2] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun 130012, Peoples R China
[3] Jilin Canc Hosp, Biobank, Changchun 130012, Peoples R China
关键词
Lung cancer; PIK3CA; ctDNA; Tissue; NGS; PROGNOSTIC-FACTOR; EGFR; KRAS; BRAF; IMMUNOTHERAPY; RESISTANCE; CARCINOMA; PLASMA; IMPACT; DRIVER;
D O I
10.1016/j.heliyon.2024.e34013
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are associated with drug resistance and prognosis in lung cancer; however, the consistency and clinical value of PIK3CA mutations between tissue and liquid samples are unknown. Methods: Circulating tumor DNA (ctDNA) and matched tumor tissue samples from 405 advanced lung cancer patients were collected at Jilin Cancer Hospital between 2018 and 2022, and the PIK3CA mutation status was sequenced using next-generation sequencing based on a 520 gene panel. The viability of different mutant lung cancer cells was detected using MTT assay. Results: PIK3CA mutations were detected in 46 (5.68 %) of 810 lung cancer samples, with 21 (5.19 %) of 405 plasma samples and 25 (6.17 %) of 405 matched tissues. p.Glu542Lys, p. Glu545Lys, and p.His1047Arg were the most common mutation types of PIK3CA in both the ctDNA and tissue samples. The concordance of PIK3CA mutations was 97.53 % between ctDNA and matched tissues (kappa: 0.770, P = 0.000), with sensitivity/true positive rate of 72.0 %, specificity/true negative rate of 99.2 %, and negative predictive value and positive predictive value of 0.982 and 0.857, respectively (AUC = 0.856, P = 0.000). Furthermore, the concordance of PIK3CA mutations was 98.26 % in lung adenocarcinoma and 96.43 % in lung squamous cell carcinoma. TP53 and EGFR were the most common concomitant mutations in ctDNA and tissues. Patients with PIK3CA mutations showed a high tumor mutational burden (TMB) (P < 0.001) and a significant correlation between bTMB and tTMB (r = 0.5986, P = 0.0041). For the tPIK3CAmut/ ctDNA PIK3CAmut cohort, PI3K pathways alteration was associated with male sex (P = 0.022), old age (P = 0.007), and smoking (P = 0.001); tPIK3CAmut/ctDNA PIK3CAwt patients harbored clinicopathological factors of adenocarcinoma stage IV, with low PS score (<= 1) and TMB. Conclusion: This study showed that ctDNA is highly concordant and sensitive for identifying PIK3CA mutations, suggesting that PIK3CA mutation detection in liquid samples may be an alternative clinical practice for tissues.
引用
收藏
页数:11
相关论文
共 40 条
[1]   Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].
Andre, Fabrice ;
Ciruelos, Eva ;
Rubovszky, Gabor ;
Campone, Mario ;
Loibl, Sibylle ;
Rugo, Hope S. ;
Iwata, Hiroji ;
Conte, Pierfranco ;
Mayer, Ingrid A. ;
Kaufman, Bella ;
Yamashita, Toshinari ;
Lu, Yen-Shen ;
Inoue, Kenichi ;
Takahashi, Masato ;
Papai, Zsuzsanna ;
Longin, Anne-Sophie ;
Mills, David ;
Wilke, Celine ;
Hirawat, Samit ;
Juric, Dejan .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940
[2]   Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Im, Seock-Ah ;
Clark, Emma ;
Ross, Graham ;
Kiermaier, Astrid ;
Swain, Sandra M. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3753-+
[3]   PIK3CA Mutations as a Prognostic Factor in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy [J].
Byun, Junssup ;
Park, Nora Jee-young ;
Yoon, Ghilsuk ;
Kang, Min Kyu ;
Kim, Hye Jin ;
Park, Soo Yeun ;
Park, Jun Seok ;
Choi, Gyu Seog ;
Baek, Jin Ho ;
Kim, Jong Gwang ;
Seo, An Na .
ANTICANCER RESEARCH, 2023, 43 (04) :1513-1520
[4]   To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations [J].
Cai, Ruoxue ;
Zhu, Hongyu ;
Liu, Ying ;
Sha, Huanhuan ;
Peng, Weiwei ;
Yin, Rong ;
Zhou, Guoren ;
Fang, Ying .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) :10027-10040
[5]   Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data [J].
Chen, Huijuan ;
Wang, Aiqin ;
Wang, Jing ;
He, Zeming ;
Mao, Yanqiu ;
Liu, Liming .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (07) :1867-1876
[6]   Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis [J].
Chen, Jie-Ying ;
Cheng, Ya-Nan ;
Han, Lei ;
Wei, Feng ;
Yu, Wen-Wen ;
Zhang, Xin-Wei ;
Cao, Shui ;
Yu, Jin-Pu .
CANCER BIOLOGY & MEDICINE, 2015, 12 (02) :126-139
[7]  
Chmielecki J, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-35961-y
[8]   Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations [J].
de Biase, Dario ;
Malapelle, Umberto ;
De Leo, Antonio ;
Maloberti, Thais ;
Visani, Michela ;
Pisapia, Pasquale ;
Acquaviva, Giorgia ;
Pepe, Francesco ;
Russo, Gianluca ;
Iaccarino, Antonino ;
Pession, Annalisa ;
Tallini, Giovanni ;
Troncone, Giancarlo .
JOURNAL OF CLINICAL PATHOLOGY, 2022, 75 (07) :488-492
[9]   The evolution of lung cancer and impact of subclonal selection in TRACERx [J].
Frankell, Alexander M. ;
Dietzen, Michelle ;
Al Bakir, Maise ;
Lim, Emilia L. ;
Karasaki, Takahiro ;
Ward, Sophia ;
Veeriah, Selvaraju ;
Colliver, Emma ;
Huebner, Ariana ;
Bunkum, Abigail ;
Hill, Mark S. ;
Grigoriadis, Kristiana ;
Moore, David A. ;
Black, James R. M. ;
Liu, Wing Kin ;
Thol, Kerstin ;
Pich, Oriol ;
Watkins, Thomas B. K. ;
Naceur-Lombardelli, Cristina ;
Cook, Daniel E. ;
Salgado, Roberto ;
Wilson, Gareth A. ;
Bailey, Chris ;
Angelova, Mihaela ;
Bentham, Robert ;
Martinez-Ruiz, Carlos ;
Abbosh, Christopher ;
Nicholson, Andrew G. ;
Le Quesne, John ;
Biswas, Dhruva ;
Rosenthal, Rachel ;
Puttick, Clare ;
Hessey, Sonya ;
Lee, Claudia ;
Prymas, Paulina ;
Toncheva, Antonia ;
Smith, Jon ;
Xing, Wei ;
Nicod, Jerome ;
Price, Gillian ;
Kerr, Keith M. ;
Naidu, Babu ;
Middleton, Gary ;
Blyth, Kevin G. ;
Fennell, Dean A. ;
Forster, Martin D. ;
Lee, Siow Ming ;
Falzon, Mary ;
Hewish, Madeleine ;
Shackcloth, Michael J. .
NATURE, 2023, 616 (7957) :525-+
[10]   Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer [J].
Guibert, N. ;
Hu, Y. ;
Feeney, N. ;
Kuang, Y. ;
Plagnol, V. ;
Jones, G. ;
Howarth, K. ;
Beeler, J. F. ;
Paweletz, C. P. ;
Oxnard, G. R. .
ANNALS OF ONCOLOGY, 2018, 29 (04) :1049-1055